The interventions initially designed for osteoarthritis (OA) can extend into a comprehensive strategy to combat multiple facets of aging. By testing in aged canine patients —a species that shares both human-like aging trajectories and spontaneous OA - we are uniquely positioned to accelerate translation into human therapies. This program is advanced in collaboration between USC and Colorado State University - Dr Nicole Erhardt (on photo) and Dr Felix Duerr.
Building on our track record of pioneering discoveries such as CX-011 and Plurocart, The Accelerator has launched the Arthritis Plus Program—an innovative research platform designed to move beyond treating osteoarthritis (OA) alone. Our program focuses on developing and testing novel small molecules developed by our, with the goal of preventing not only age-associated OA but also the constellation of conditions that often accompany it: frailty, metabolic disorders and cognitive decline. These age-related effects frequently emerge alongside arthritis, creating a cycle of disability and diminished quality of life.
​​​
Through the Arthritis Plus Program, we are working to break this cycle. By targeting the biological mechanisms that drive joint degeneration and systemic inflammation, our team aims to:​
-
Delay or prevent OA progression through disease-modifying therapeutics.
-
Reduce frailty and muscle loss, preserving strength and mobility.
-
Mitigate cognitive decline, enhancing long-term brain health.
​​
Our story is rooted in a passion innovation and
a commitment to making
a difference in our community.
Discover the exciting range of activities we offer to your experience and engage with our vibrant community.
